We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

126 hedge funds and large institutions have $1.62B invested in Recursion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 52 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

420% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 10

382% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 11

132% more call options, than puts

Call options by funds: $2.03M | Put options by funds: $878K

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

50% more funds holding

Funds holding: 84 → 126 (+42)

28% more capital invested

Capital invested by funds: $1.26B → $1.62B (+$352M)

24.61% more ownership

Funds ownership: 34.53% → 59.14% (+25%)

Holders
126
Holders Change
+42
Holders Change %
+50%
% of All Funds
1.94%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
53
Increased
52
Reduced
10
Closed
11
Calls
$2.03M
Puts
$878K
Net Calls
+$1.16M
Net Calls Change
+$101K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$94M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$64M
3
State Street
State Street
Massachusetts
+$56.7M
4
AI
ArchPoint Investors
Florida
+$23.6M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$23.3M

Top Sellers

Rank Fund Capital Flow
1
CL
CRV LLC
California
-$16.9M
2
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.6M
3
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
-$8.68M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.09M
5
AIM
ARK Investment Management
Florida
-$6.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
76
UBS AM
Illinois
$607K +$667K +35,453 New
DekaBank Deutsche Girozentrale
77
DekaBank Deutsche Girozentrale
Germany
$592K +$659K +35,000 New
Russell Investments Group
78
Russell Investments Group
United Kingdom
$584K +$49.5K +2,633 +8%
CSS
79
Cubist Systematic Strategies
Connecticut
$579K +$115K +6,091 +22%
Millennium Management
80
Millennium Management
New York
$579K +$637K +33,829 New
MLICM
81
Metropolitan Life Insurance Company (MetLife)
New York
$523K +$421K +22,388 +275%
HLA
82
Hamilton Lane Advisors
Pennsylvania
$465K +$510K +27,123 New
SEC
83
Seven Eight Capital
New York
$445K +$489K +26,001 New
CF
84
CNA Financial
Illinois
$442K +$174K +9,250 +56%
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
$425K +$413K +21,954 +771%
SG Americas Securities
86
SG Americas Securities
New York
$391K +$199K +10,576 +86%
SO
87
STRS Ohio
Ohio
$387K +$301K +16,000 +242%
Legal & General Group
88
Legal & General Group
United Kingdom
$355K +$340K +18,047 +667%
AB
89
Amalgamated Bank
New York
$317K +$349K +18,534 New
Jane Street
90
Jane Street
New York
$309K +$340K +18,065 New
Zurich Cantonal Bank
91
Zurich Cantonal Bank
Switzerland
$275K +$155K +8,239 +105%
WAM
92
Weiss Asset Management
Massachusetts
$272K +$299K +15,880 New
Mitsubishi UFJ Asset Management
93
Mitsubishi UFJ Asset Management
Japan
$270K +$281K +14,957 New
Ensign Peak Advisors
94
Ensign Peak Advisors
Utah
$265K +$291K +15,470 New
CGL
95
Clarius Group LLC
Washington
$233K +$256K +13,600 New
FIA
96
Foundations Investment Advisors
Arizona
$231K +$101K +5,359 +52%
Handelsbanken Fonder
97
Handelsbanken Fonder
Sweden
$228K +$250K +13,300 New
TI
98
Trexquant Investment
Connecticut
$206K +$227K +12,050 New
ASRS
99
Arizona State Retirement System
Arizona
$183K +$201K +10,700 New
Rockefeller Capital Management
100
Rockefeller Capital Management
New York
$178K +$157K +8,347 +407%
2 3
4
5 6

RXRX Hedge Fund Activity: Q4 2021 in Review

126 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2021, worth a combined $1.62B — up 28% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new RXRX positions and 11 closed out — a net gain of 42 holders — while 52 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $94M. The largest seller was CRV LLC, exiting entirely with an estimated $16.9M sold.

  • 126 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2021, up from 84 in Q3 2021.
  • Funds reported $1.62B of Recursion Pharmaceuticals stock for Q4 2021, up 28% quarter-over-quarter.
  • 53 funds opened new Recursion Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +42 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $94M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2021 was CRV LLC, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2021.